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Abstract
Many patients with muscle-invasive bladder cancer (BC) are either ineligible for or do
not benefit from cisplatin-based chemotherapy, and there is an unmet need to estimate
individuals’ drug sensitivities. We investigated the suitability of conditionally repro-
grammed (CR) cells for the characterization of BC properties and their feasibility for
personalized drug sensitivity screening. The CR cultures were established from six BC
tumors with varying histology and stage. Four cultures were successfully propagated for
genomic, transcriptomic, and protein expression profiling and compared to the parental
tumors. Two out of four CR cultures (urothelial carcinoma and small cell neuroendocrine
carcinoma [SmCC]) corresponded well to their parental tumors and underwent drug
sensitivity screening to identify novel drugs for the respective tumors. Both cultures
were sensitive to standard BC chemotherapy agents (eg cisplatin and gemcitabine) and
to conventional drugs such as taxanes and inhibitors of topoisomerase and proteasome.
The SmCC cells were also sensitive to statins (eg, atorvastatin and pitavastatin). In
summary, after confirming their representativeness and origin, we conclude that CR
cells are a feasible platform for personalized drug sensitivity testing and might thus add
to the approaches used to personalize BC treatment strategies.
Patient summary: We investigated the conditional reprogramming method for gener-
ating patient-derived bladder cancer cell cultures and studied their feasibility for
planning personalized treatment strategies.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author. Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520
Turku, Finland. Tel. +358 29 450 4524.
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0302-2838/© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Muscle-invasive bladder cancer (BC) is a mutationally
heterogeneous malignancy with poor survival. Almost half
of patients with this disease are ineligible for cisplatin-
based adjuvant or neoadjuvant chemotherapy, and only a
subset benefits from treatment [1]. Currently there are no
validated means in the clinical setting to predict
chemotherapy responses and/or clinical outcomes.
As BC is characterized by a lack of common druggable
driver mutations and high intertumor heterogeneity,
recapitulation of tumor characteristics ex vivo would offer
tools for studying drug sensitivities for individual patients
upfront and potential novel treatment approaches. Various
patient-derived organoid and xenograft BC models have
recently been established and used to identify personalized
drug sensitivities [2]. Although these three-dimensional
(3D)models replicate the tumor environment, it may not be
feasible to use them for routine high-throughput diagnos-
tics because of limitations associated with the culture
complexity and the inability to accurately assess responses
at the individual cell level.
Conditional reprogramming (CR) is a method that allows
rapid expansion of malignant and normal epithelial cells
without genetic manipulation. The CR approach has been
used to generate patient-derived cultures from various
neoplasms, including prostate cancer and respiratory
papillomatosis [3,4]; however, the method has not been
applied in human BC. The main challenge has been the
overgrowth of benign epithelial cells, highlighting the need
for stringent sampling of tumor material and validation of
the origin of the cells via sequencing [5].
We applied the CR platform to generate patient-derived
cell cultures from six BC patients undergoing cystectomy or
transurethral resection (Fig. 1A). Four patients had pTaN0–
T4N1 high-grade urothelial carcinoma (HG-UC), one patient
had pT4aN1 small-cell neuroendocrine carcinoma (SmCC),
and one patient had pT2bN1 primary bladder adenocarci-
noma (Fig. 1A and B, Supplementary Table 1). The cultures
were established according to a published CR procedure [6]
with some modifications (Supplementary material). The
cultures were considered stably established if they could be
cultured for five passages, and after cryopreservation
repropagated for follow-up analysis.
Four (3 HG-UCs and 1 SmCC) out of six CR cultures were
successfully repropagated after cryopreservation (success
rate 67%; Supplementary Table 1) and were denoted HG-Ta-
CR, HG-T1-CR, HG-T4-CR, and SmCC-T4-CR. All the urothelial
CR cultures shared typical CR culture morphology, while the
SmCC-T4-CR cells had the expected smaller cellular size
(Fig. 1C and E). HG-T1-CR and SmCC-T4-CR cells showed
exponential growth during 30-d follow-up (Fig. 1D). Exome
sequencing analysis showed that two of the cultures (HG-T1-
CR and SmCC-T4-CR) retained the majority of mutations (eg,
in RB1) found in the corresponding tumors, whereas the HG-
Ta-CR andHG-T4-CR cultures did not, suggesting that normal
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Fig. 1 – Establishment of conditionally reprogrammed (CR) cultures. (A) Overview of the study design. CR cultures were established from fresh tumor
samples obtained from radical cystectomy (RC) or transurethral resection of bladder tumor (TUR-BT). The cultures and the corresponding tumor
samples were characterized by immunohistochemical (IHC) analyses, Western blotting, and whole-exome DNA sequencing and RNA sequencing. Finally,
high-throughput drug sensitivity screening was performed on the cancerous CR cultures. (B) Histology of parental tumors (low- and high-power
magnifications). Three patients had high-grade (HG) urothelial carcinoma staged as pTa, pT1, and pT4aN1 (HG-Ta, HG-T1 and HG-T4, respectively;
hematoxylin and eosin stain), and one patient had small cell neuroendocrine carcinoma (SmCC; Van Gieson stain) staged as pT4aN1 (SmCC-T4). Scale
bars, 100mm. Only tumors with stably established CR cultures are shown. (C) Representative phase-contrast microscopy image showing the typical cell
morphology of a CR culture (example from HG-T1 CR). Scale bars, 50mm. (D) Proliferation assays of HG-T1-CR and SmCC-T4-CR cultures. Both cultures
showed exponential growth over the 30-d follow-up period. (E) May-Grünwald Giemsa-stained cytospin samples from CR cultures. SmCC-T4-CR cells
showed an overall smaller cellular size compared to cells from urothelial carcinomas. Scale bars, 50mm.
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Fig. 2 – Characterization of conditionally reprogrammed (CR) cultures and their parental tumors. (A) For each tumor and cell-line pair, Venn diagrams
depict the total number of mutations per sample with the number of co-occurring mutations shown in the overlapping circles. Tumor samples are
depicted in green and cell cultures in blue. HG-T1-CR and SmCC-T4-CR cells retained the majority of mutations found in the corresponding tumors,
whereas HG-Ta-CR and HG-T4-CR did not. (B) Top panel: Tumor mutation burden shown as synonymous (green) and nonsynonymous (blue) mutation
rates per Mb. Bottom panel: The significantly mutated genes in the CR cultures (C) and in the corresponding tumors (T), as reported in The Cancer
Genome Atlas BC cohort [11]. Only the exonic or splicing mutations found in either HG-T1 or SmCC-T4 tumors/cells are shown. Supplementary Fig.
1 and Supplementary Tables 2 and 3 show individual mutations also found in HG-Ta and HG-T4 tumors/cells. (C) Immunohistochemistry analysis of CR
cultures and the HG-T1 and SmCC-T4 parental tumors shown as a heat map. The HG-T1 tumor shows characteristics of the luminal type, while the CR
culture shows transition towards a more basaloid/squamous phenotype as observed by the expression of keratin 5/6 (CK5/6) and reduced expressions
of keratin 20 (CK20) and GATA3 in the corresponding CR culture. The SmCC-T4 tumor and CR culture correspond to the neuronal type. The number
indicates the percentage of positively stained cells. CGA = chromogranin A. (D) Gene expression clustering analysis shows distinct sample groups
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epithelial cells had overgrown in these two cultures (Fig. 2A
and B, Supplementary Fig. 1, Supplementary Tables 2 and 3).
On immunohistochemical analysis, HG-T1-CR cells
showed strong keratin 5/6 expression, indicating a shift
towards amore basaloid phenotype (Fig. 2C, Supplementary
Fig. 2). In SmCC-T4-CR cells, strong expression of neuroen-
docrine markers and loss of keratins were detected, similar
to the parental tumor (Fig. 2C, Supplementary Fig. 2). Both
cancer-originating cultures were strongly p53-positive and
showed a higher percentage of Ki-67-positive cells when
compared to noncancerous cultures (Fig. 2C, Supplementa-
ry Figs. 2 and 3).
In RNA sequencing and gene set enrichment analysis, the
expression of cell adhesion-related transcripts clearly
differentiated the primary tumors from CR cells cultured
in the absence of stromal cells (Fig. 2D and E). Genes
representative of basal cell fate (eg, KRT5, KRT6, KRT17, and
KRT19) were enriched in CR cultures of urothelial origin,
while SmCC-T4-CR and the parental tumor were distinct
from the other cultures and tumors on the basis of strong
expression of neuroendocrine genes. TheCR cultures showed
very little gain of functionality compared to the primary
tumors. However, there was some increase in translation-
related pathways and ribogenesis. Furthermore, the cancer-
originatingcultures exhibited significantlyhigherexpression
of various cell cycle-related genes and lower expression of
CCND1/CCND2 (due to loss of RB1) compared to the
noncancerous cultures (Supplementary Table 4).
Drug sensitivity screening performed on cancer-origi-
nating cultures showed sensitivity to platinum-based
drugs, taxanes, topoisomerase inhibitors, and proteasome
inhibitors, independent of the difference in the proliferation
rates of the cell cultures (Fig. 2F, Supplementary Fig. 4). The
HG-T1-CR cells were resistant to the EGFR inhibitor
erlotinib (in line with the activating E322K mutation
detected in MAPK1) while the SmCC-T4-CR cells were
highly responsive to statins at low concentrations. The
effects of cisplatin (standard treatment) and atorvastatin
(because of a high statin response) were further validated
with more detailed sensitivity measurements, with highly
similar results compared to screening obtained (Fig. 2G).
In the current study we demonstrated the feasibility of
establishing patient-derived BC CR cultures that retain the
hallmark mutations of the primary tumor without signifi-
cant phenotypic drift. Furthermore, the CR cultures were
suitable for drug sensitivity screening. Exome sequencing
analysis demonstrated that two of the four CR cultures
characterized matched the corresponding tumor, as seen in
the previous studies [3]. However, the other two CR cultures
failed to retain the specific driver mutations found in their
parental tumors, suggesting contamination by nonmalig-
nant cells. Therefore, detailed selection of original tumor
material and genomic analysis are crucial to confirm the
origin of the established culture.
The results of personalized drug screening are of
particular interest and might point to novel therapy targets
for individual patients or subgroups. While clinically used
platin-based compoundswere effective in the CR cultures in
vitro, we also observed high sensitivity of SmCC-T4-CR cells
to statins, which could be a promising, well-tolerated, and
low-cost candidate for further studies. The specific mecha-
nism of statins depends on the type of statin used and the
type of cancer cells. In case of small cell lung cancer, the
mechanism seems to be HMG-CoA reductase inhibition of
cholesterol biosynthesis and subsequent impairment of Ras
signaling [7]. In addition, for some urothelial BC cell
cultures, statins appear to induce cell cycle arrest and
inhibit proliferation via the PPARg signaling pathway [8].
While the results from the current study are encourag-
ing, the data are limited by the small number of the cultures
produced and potential intratumor heterogeneity. Culture
conditions, including the culture media used and the
absence of stromal and inflammatory cells, may also affect
the tumor microenvironment and drug sensitivities
[9,10]. Since conditioned media appear to be a prerequisite
for successful culture, a more detailed characterization of
the impact on drug sensitivities during the development of
rapid 3D culturemodels needs to be tested in future studies.
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